Clinical trials: Metastatic Differentiated Thyroid Gland Carcinoma
Papillary Thyroid Cancer
Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma
Primary objective: The 3-years disease-free survival was compared between low-dose group (30 mCi) and high-dose group (100 mCi).
- Trial name
- NCT04354324
- Testing
- Radioiodine
- Where
- China
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital